Shuttle Pharmaceuticals Holdings, Inc.

SHPH

US8256932034

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-21 EDT			5-day change	1st Jan Change
0.428 ^USD	+2.98%		+3.38%	-5.93%

03-21	Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-07	Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $2.25 million in funding	CI

Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 25, 2023 at 05:22 pm

Shuttle Pharmaceuticals Holdings, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 0.975097 million compared to USD 0.681839 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.07 a year ago.

Latest news about Shuttle Pharmaceuticals Holdings, Inc.

Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $2.25 million in funding	02-06	CI
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma	01-08	CI
Shuttle Pharmaceuticals Holdings, Inc. Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma	12-11	CI
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Shuttle Pharma Gets FDA Letter With Positive Feedback for Ropidoxuridine	23-09-25	DJ
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma	23-09-25	CI
Shuttle Pharmaceuticals Holdings, Inc.(NasdaqCM:SHPH) added to S&P TMI Index	23-09-18	CI
Shuttle Pharmaceuticals Holdings, Inc. Expands Patent Coverage on HDAC Inhibitor Platform	23-09-11	CI
Top Premarket Gainers	23-09-08	MT
Certain Common Stock of Shuttle Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 30-AUG-2023.	23-08-29	CI
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient for Use in Clinical Trial	23-08-03	CI
Top Premarket Gainers	23-05-26	MT
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Shuttle Pharmaceuticals, Georgetown University Sign Research Deal to Evaluate Anti-Tumor Candidates	23-03-22	MT
Shuttle Pharmaceuticals Holdings, Inc. Auditor Raises 'Going Concern' Doubt	23-03-14	CI
Shuttle Pharmaceuticals Signs Ropidoxuridine Manufacturing Deal With University of Iowa Pharmaceuticals	23-03-09	MT
Certain Common Stock of Shuttle Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 2-MAR-2023.	23-03-01	CI
Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities	23-02-23	CI
Sector Update: Health Care Stocks Steady Friday Afternoon While Other Sectors Rebound	23-01-13	MT
Sector Update: Health Care Standing Firm as Broader Markets Catch Up	23-01-13	MT
Sector Update: Health Care	23-01-13	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	23-01-13	MT
Sector Update: Health Care	23-01-13	MT

Chart Shuttle Pharmaceuticals Holdings, Inc.

Duration

Period

Chart Shuttle Pharmaceuticals Holdings, Inc.

More charts

Company Profile

Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHUTTLE PHARMACEUTICALS HOLDINGS, INC.	-5.93%	7.2M
ELI LILLY AND COMPANY	+37.78%	723B
NOVO NORDISK A/S	+30.97%	598B
JOHNSON & JOHNSON	-3.51%	364B
MERCK & CO., INC.	+19.94%	331B
ABBVIE INC.	+5.14%	288B
ASTRAZENECA PLC	+16.51%	244B
ROCHE HOLDING AG	-4.54%	208B
NOVARTIS AG	+10.13%	210B
AMGEN INC.	+9.32%	169B

Other Pharmaceuticals